Arcadia Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
RKDA$0.17+3.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share data)
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $1,120 | $4,242 |
| Short-term investments | 4,765 | — |
| Accounts receivable and other receivables, net of allowance for credit losses of $559 and $0 as of September 30, 2025 and December 31, 2024, respectively | 831 | 1,175 |
| Inventories | 1,457 | 904 |
| Note receivable — current, net of allowance for credit losses (Note 7) | — | 1,894 |
| Prepaid expenses and other current assets | 214 | 931 |
| Current assets of discontinued operations — GoodWheat | — | 96 |
| Total current assets | 8,387 | 9,242 |
| Property and equipment, net | 10 | 41 |
| Right of use asset | — | 137 |
| Intangible assets, net | 39 | 39 |
| Note receivable — noncurrent, net of allowance for credit losses (Note 7) | — | 3,966 |
| Other noncurrent assets | 148 | 92 |
| Total assets | $8,584 | $13,517 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $2,015 | $2,108 |
| Amounts due to related parties | — | 30 |
| Operating lease liability — current | — | 155 |
| Other current liabilities | 270 | 270 |
| Total current liabilities | 2,285 | 2,563 |
| Common stock warrant and option liabilities | 856 | 2,731 |
| Other noncurrent liabilities | — | 2,000 |
| Total liabilities | 3,141 | 7,294 |
| Commitments and contingencies (Note 14) | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par value—150,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 1,367,429 and 1,364,940 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 65 | 65 |
| Additional paid-in capital | 285,259 | 285,036 |
| Accumulated deficit | (279,881) | (278,878) |
| Total stockholders' equity | 5,443 | 6,223 |
| Total liabilities and stockholders’ equity | $8,584 | $13,517 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.